Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EGXK | ISIN: SE0020353928 | Ticker-Symbol: MB8
Tradegate
27.06.25 | 19:23
0,786 Euro
-1,63 % -0,013
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MOBERG PHARMA AB Chart 1 Jahr
5-Tage-Chart
MOBERG PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,7730,82313:03
0,7860,81227.06.

Aktuelle News zur MOBERG PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiChanges to Moberg Pharma's Management2
16.06.MOBERG PHARMA AB: Terclara market leader also in Norway1
03.06.MOBERG PHARMA AB: The board of directors exercises authorizations to issue and repurchase C-shares, and converts class C shares to common shares1
22.05.Bulletin from Moberg Pharma's AGM on May 22[th], 20253
MOBERG PHARMA Aktie jetzt für 0€ handeln
13.05.Moberg Pharma AB: Moberg Pharma interim report January - March 202581TERCLARA NOW ALSO AVAILABLE IN NORWAY FIRST QUARTER (JAN-MAR 2025) Net revenue SEK 3.9 million (0.8) EBITDA SEK -3.7 million (-7.6) Operating profit (EBIT) SEK -4.1 million (-7.9) Profit for...
► Artikel lesen
22.04.Notice of Annual General Meeting in Moberg Pharma AB (publ)1
11.02.Moberg Pharma AB: Moberg Pharma Year-end report 2024195TERCLARA CONTINUES TO LEAD THE MARKET AND EXPANDS TO NORWAY THE YEAR (JAN-DEC 2024) Net revenue SEK 9.8 million (0) EBITDA SEK -23.5 million (-25.4) Operating profit (EBIT) SEK -324.8 million...
► Artikel lesen
03.02.MOBERG PHARMA: Terclara (MOB-015) is now being launched in Norway3
10.12.24Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU185STOCKHOLM, Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase...
► Artikel lesen
12.11.24Moberg Pharma AB: Moberg Pharma's Interim report January - September 2024187TERCLARA WINS LAUNCH OF THE YEAR AT KRONANS PHARMACY AND DOZ PHARMACY NINE-MONTH PERIOD (JAN-SEP 2024) Net income SEK 8.8 million (0) EBITDA SEK -15.7 million (-17.4) Operating profit (EBIT) SEK...
► Artikel lesen
13.09.24Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients337STOCKHOLM, Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American...
► Artikel lesen
13.08.24Moberg Pharma AB: Moberg Pharma's interim report January - June 2024186TERCLARA IS THE MARKET LEADER IN SWEDEN SIX-MONTH PERIOD (JAN-JUNE 2024) Net revenue SEK 4.9 million (0) EBITDA SEK -12.7 million (-10.7) Operating profit (EBIT) SEK -13.4 million (-12.0) Profit...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1